Not a good buy right now: trend and momentum are bearish (bearish MA stack + MACD deteriorating) and the pattern-based forecast skews negative across 1D/1W/1M.
Price is sitting right at/just below near-term support (~11.99) in pre-market (11.94). That can produce bounces, but there’s no proprietary buy signal today to justify an impatient entry.
With earnings on 2026-02-12 after hours and the stock already weak, risk/reward for buying immediately is unfavorable. Best decision now: avoid new buys / hold only if already positioned and willing to tolerate an earnings-driven move.
Technical Analysis
Trend: Bearish (SMA_200 > SMA_20 > SMA_5), indicating sustained downside pressure across long-, mid-, and short-term horizons.
Momentum: MACD histogram -0.108 and negatively expanding -> downside momentum is strengthening rather than stabilizing.
RSI: RSI_6 at 26.18 suggests short-term oversold conditions (despite the provided label), which can support a brief bounce, but oversold is not a reliable “buy” signal when trend/momentum remain bearish.
Key levels: Pivot 12.774 (price below pivot = bearish). Immediate support S1 ~11.991 (price ~11.94 is slightly below), next support S2 11.507. Resistance levels to reclaim: 12.77 then 13.56.
Quant/pattern outlook: Similar-pattern study implies ~70% chance of further weakness (-1.12% next day, -1.39% next week, -4.99% next month).
supports long-term operating leverage if revenue growth accelerates.
Neutral/Negative Catalysts
Technical setup is decisively bearish (bearish MA stack + worsening MACD), making immediate entries low quality for an impatient buyer.
Earnings event risk on 2026-02-12: with the stock weak, a miss or cautious guidance can accelerate downside.
News flow provided is largely about European large-caps (Carlsberg/Novo Nordisk) and is broadly negative on consumer demand—this does not appear to be a direct CARL-specific catalyst, but it doesn’t help overall sentiment.
No supportive positioning signal: hedge fund and insider trends are neutral (no “smart money” confirmation in the dataset).
Financial Performance
Latest quarter provided: 2025/Q3.
Revenue: 13.074M, reported as 0.00% YoY change (flat growth in the provided snapshot).
Profitability: Net income -8.526M and EPS -0.40 (still loss-making; snapshot shows 0.00% YoY change).
Margins: Gross margin 75.93% (strong on a gross basis, but not yet translating into bottom-line profitability).
Takeaway: quality gross margins, but growth/profit inflection is not evident in the provided YoY figures.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent direction (overall): generally positive, with multiple Buy ratings and raised price targets in the feed.
Carlsmed-specific: BTIG (2025-11-07) maintained Buy and raised PT to $24 after a Q3 beat, highlighting surgeon growth/productivity.
Also listed: Goldman Sachs raised PT to $20 and kept Buy (dated 2026-01-09) — supportive if it indeed pertains to CARL.
Data quality note: several entries reference “Carlsberg” with DKK price targets, which likely belong to a different company and should not be relied on for CARL.
Wall Street pros vs cons (from what’s usable here): Pros—supportive Buy stances and targets implying material upside vs current price; Cons—current tape/technicals contradict bullish fundamentals narrative, and near-term entry timing looks poor without a catalyst or proprietary buy signal.
Wall Street analysts forecast CARL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CARL is 20.5 USD with a low forecast of 18 USD and a high forecast of 24 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast CARL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CARL is 20.5 USD with a low forecast of 18 USD and a high forecast of 24 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 11.290
Low
18
Averages
20.5
High
24
Current: 11.290
Low
18
Averages
20.5
High
24
Goldman Sachs
Buy
maintain
$19 -> $20
AI Analysis
2026-01-09
Reason
Goldman Sachs
Price Target
$19 -> $20
AI Analysis
2026-01-09
maintain
Buy
Reason
Goldman Sachs raised the firm's price target on Carlsmed to $20 from $19 and keeps a Buy rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.
Deutsche Bank
Mitch Collett
Buy
maintain
2026-01-07
Reason
Deutsche Bank
Mitch Collett
Price Target
2026-01-07
maintain
Buy
Reason
Deutsche Bank analyst Mitch Collett raised the firm's price target on Carlsberg to DKK 1,160 from DKK 1,130 and keeps a Buy rating on the shares.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CARL
